Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Open Access
Publisher Website
Google Scholar
Abstract
HER2 is a well-known proto-oncogene encoding a transmembrane glycoprotein with tyrosine kinase activity. This protein is reported to have prognostic and predictive roles in breast cancer, and it is supposed to be involved with early pathogenesis of breast cancer. A polymorphism at codon 655 (Ile to Val; Ile655Val) in the transmembrane domain region of this gene was identified; a recent population-based case–control study in Shanghai, China (1), revealed that women with the Ile/Val or Val/Val genotype had an elevated risk for breast cancer and that among women with the Val/Val genotype the risk was even more elevated. Subsequently, Ameyaw et al. (2) reported that the distribution of this HER2 polymorphism (Val655Ile) varied considerably between ethnic groups, with the Val655 allele detected in 20% of the Caucasians examined but absent in an African population. Afterward, several studies (3– 6) were conducted on the association between the HER2 Val655Ile polymorphism and the risk of breast cancer among Caucasians, Africans, and Latinos, but no statistically significant association was observed. However, the possibility that a marked association could be observed in Asian populations was not ruled out.

This publication has 0 references indexed in Scilit: